Phaarmasia Limited (BOM:523620)

Market Cap	810.36M +152.6%
Revenue (ttm)	449.06M +55.2%
Net Income	177.54M
EPS	25.99
Shares Out	6.83M
PE Ratio	4.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,714
Average Volume	2,880
Open	119.96
Previous Close	119.96
Day's Range	113.97 - 123.97
52-Week Range	23.60 - 131.75
Beta	0.99
RSI	64.10
Earnings Date	Feb 6, 2026

About Phaarmasia

Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, an...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 36
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 523620

Financial Performance

In fiscal year 2025, Phaarmasia's revenue was 243.69 million, a decrease of -20.35% compared to the previous year's 305.93 million. Losses were -15.89 million, 206.7% more than in 2024.